Regencell Bioscience Shares Continue to Rise 124%, Shares Have Gained 180 Times This Year

Tiger Newspress
07-03

Regencell Bioscience shares continued to rise 124%, shares have gained 180 times this year.

The money-losing traditional Chinese medicine company blamed short sellers for last month’s massive stock gain, which briefly boosted its chief executive officer’s paper wealth to one of the world’s 100 largest fortunes.

Hong Kong-based Regencell Bioscience Holdings Ltd., which develops herbal treatments for ADHD and autism, saw its shares soar more than 82,000% from a February low. The company’s stock has since fallen about 80%.

In interim financial results released Monday, Regencell — which has reported six consecutive years of net losses — pointed to short sellers as a possible cause of its stock’s extreme volatility.

“We believe that a ‘short squeeze’ due to a sudden increase in demand for our ordinary shares that largely exceeds supply has led to, and may continue to lead to, extreme price volatility,” according to the filing. It added that nothing has changed about its operating performance or financial position.

At the shares’ June 17 peak, founder Yat-Gai Au’s 86% stake was worth $33.3 billion, according to the Bloomberg Billionaires Index, putting him ahead of such rich-list stawarts as Phil Knight and Masayoshi Son. His net worth has since dropped to $6.8 billion.

Some experts, including S3 Partners’ Ihor Dusaniwsky, questioned Au’s explanation for the price swings, saying “it doesn’t hold water.”

Regencell’s current short interest is only about 1 million shares, or just 3% of the company’s already low float, data from S3 Partners shows. Given those numbers, it’s unlikely that short sellers wield enough muscle to move the share price significantly, Dusaniwsky said.

“Looking at the size of the short selling compared to the trading volume, it can’t be the cause,” Dusaniwsky, the firm’s managing director of predictive analytics, said in an interview.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10